Cargando…

Structural Insights into the Abscisic Acid Stereospecificity by the ABA Receptors PYR/PYL/RCAR

The phytohormone abscisic acid ((+)-ABA) plays a key role in many processes. The biological and biochemical activities of unnatural (−)-ABA have been extensively investigated since 1960s. However, the recognition mechanism by which only a few members among PYR/PYL/RCAR (PYLs) family can bind (−)-ABA...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xingliang, Jiang, Lun, Wang, Guoqiang, Yu, Lin, Zhang, Qi, Xin, Qi, Wu, Wei, Gong, Zhizhong, Chen, Zhongzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699650/
https://www.ncbi.nlm.nih.gov/pubmed/23844015
http://dx.doi.org/10.1371/journal.pone.0067477
Descripción
Sumario:The phytohormone abscisic acid ((+)-ABA) plays a key role in many processes. The biological and biochemical activities of unnatural (−)-ABA have been extensively investigated since 1960s. However, the recognition mechanism by which only a few members among PYR/PYL/RCAR (PYLs) family can bind (−)-ABA remains largely unknown. Here we systematically characterized the affinity of PYLs binding to the (−)-ABA and reported the crystal structures of apo-PYL5, PYL3-(−)-ABA and PYL9-(+)-ABA. PYL5 showed the strongest binding affinity with (−)-ABA among all the PYLs. PYL9 is a stringently exclusive (+)-ABA receptor with interchangeable disulfide bonds shared by a subclass of PYLs. PYL3 is a dual receptor to both ABA enantiomers. The binding orientation and pocket of (−)-ABA in PYLs are obviously different from those of (+)-ABA. Steric hindrance and hydrophobic interaction are the two key factors in determining the stereospecificity of PYLs binding to (−)-ABA, which is further confirmed by gain-of-function and loss-of-function mutagenesis. Our results provide novel insights of the bioactivity of ABA enantiomers onto PYLs, and shed light on designing the selective ABA receptors agonists.